A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis
Makaleler > Tam Makale · 2011
Yazarlar: Devrim BOZKURT, Banu SARSIK KUMBARACI, Ender HUR, Muhittin ERTILAV, Burcak KARACA, Ozge TİMUR, Selahattin BIÇAK, Selahattin Fehmi AKÇİÇEK, Soner DUMAN
JOURNAL OF NEPHROLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2011, cilt 24, ss 359-365
DOI: 10.5301/jn.2010.6257
Özet
Introduction: Encapsulated peritoneal sclerosis (EPS) is characterized by neoangiogenesis and fibrosis. Increased inflammation is the leading cause of EPS. In turn, neoangiogenesis is both a consequence of and contributor to inflammation. The effects of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, have been postulated in various antiangiogenesis, antiinflammatory and antifibrotic processes both in vitro and in vivo. This novel angiogenesis inhibitor, Sutent (sunitinib malate), was investigated in our rat EPS model.